VERAXA Biotech AG (NASDAQ: VRXA) announced the appointment of Christoph Erkel, Ph.D., as chief scientific officer, effective immediately. Erkel, who previously served as vice president of research and development, will lead the advancement of the company’s proprietary BiTAC(R) platform technologies for developing cancer therapies targeting solid tumors. He succeeds Rick Austin, Ph.D., who will depart after a transition period.
Erkel brings two decades of experience in antibody therapeutics, antibody engineering, and preclinical development. His prior leadership roles at MorphoSys AG included directing immuno-oncology programs focused on T-cell engagers. VERAXA said his experience managing multidisciplinary research programs will support efforts to expand the company’s oncology pipeline and advance BiTAC(R) candidates toward clinical development.
The appointment comes as VERAXA accelerates its pipeline of bispecific T-cell engagers, bispecific ADCs, and other innovative antibody formats. The company’s BiTAC platform is designed to enhance tumor targeting and immune activation, potentially improving outcomes for patients with solid tumors. The full press release is available at https://nnw.fm/cR1RS.
VERAXA was founded on scientific breakthroughs at the European Molecular Biology Laboratory (EMBL), a world-renowned institution for life science research. The company’s quality-by-design approach aims to rapidly advance its pipeline into clinical development. BiTAC(R) is a registered trademark of VERAXA Biotech GmbH.
This leadership change signals VERAXA’s commitment to advancing its oncology pipeline and leveraging Erkel’s expertise in antibody engineering to drive innovation. The company’s focus on solid tumors addresses a significant unmet medical need, as many immunotherapies have shown limited efficacy in these indications. With Erkel at the helm of R&D, VERAXA aims to overcome these challenges through its proprietary platform technologies.
The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA. Forward-looking statements in this release involve risks and uncertainties, as detailed in the company’s SEC filings. All parties undertake no duty to update this information unless required by law.
